AssetMark Inc
FULC icon

AssetMark Inc’s Fulcrum Therapeutics FULC Stock Holding History

AssetMark Inc’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$57.7K Sell
7,525
-659
-8% -$6.11K ﹤0.01% 1708
2025
Q4 		$92.6K Sell
8,184
-1,427
-15% -$14.5K ﹤0.01% 1521
2025
Q3 		$88.4K Buy
+9,611
New +$69.5K ﹤0.01% 1467

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

AssetMark Inc's FULC Position: Q1 2026 in Review

AssetMark Inc reduced its Fulcrum Therapeutics (FULC) stake by 8.1% in Q1 2026, selling an estimated $6.11K and leaving 7,525 shares worth $57.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1708.

AssetMark Inc first reported a position in FULC in Q3 2025 and has held it in 3 quarters since. The position peaked at $92.6K in Q4 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • AssetMark Inc held 7,525 shares of Fulcrum Therapeutics worth $57.7K as of Q1 2026.
  • AssetMark Inc sold 659 Fulcrum Therapeutics shares in Q1 2026, an estimated $6.11K.
  • Fulcrum Therapeutics made up ﹤0.01% of AssetMark Inc's portfolio in Q1 2026, its #1708 holding.
  • AssetMark Inc first reported a position in Fulcrum Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • AssetMark Inc's Fulcrum Therapeutics position peaked at $92.6K in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on AssetMark Inc's 13F filing for Q1 2026, filed 6 May 2026.